TITLE

2011 - Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD

AUTHOR(S)
Wark, Peter
PUB. DATE
July 2011
SOURCE
ACP Journal Club;7/19/2011, Vol. 155 Issue 1, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study conducted by C. Vogelmeier and colleagues, focusing on the effectiveness of tiotropium in the prevention of exacerbations of chronic obstructive pulmonary disease (COPD). The findings of the study show that in patients with COPD, tiotropium is more effective than salmeterol for reducing exacerbations.
ACCESSION #
65456982

 

Related Articles

  • 2011 - Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD. Wark, Peter // ACP Journal Club;7/19/2011, Vol. 155 Issue 1, p2 

    Question In patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD), is tiotropium more effective than salmeterol for reducing exacerbations? Methods Design Randomized controlled trial (Prevention of Exacerbations with Tiotropium in COPD [POET-COPD])....

  • Anticholinergic drugs for COPD. Elliott, William T. // Neurology Alert;May2011 Clinical Bri, p1 

    The article discusses results of a study which determined if anticholinergic drugs should be the first-line agents for preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD), published in a 2011 issue of the "New England Journal of Medicine." The study methodology...

  • Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone--Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. Aaron, Shawn D.; Vandemheen, Katherine L.; Fergusson, Dean; Maltais, François; Bourbeau, Jean; Goldstein, Roger; Balter, Meyer; O'Donnell, Denis; McIvor, Andrew; Sharma, Sat; Bishop, Graham; Anthony, John; Cowie, Robert; Field, Stephen; Hirsch, Andrew; Hernandez, Paul; Rivington, Robert; Road, Jeremy; Hoffstein, Victor; Hodder, Richard // Annals of Internal Medicine;4/17/2007, Vol. 146 Issue 8, p545 

    Background: Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting β-agonists, and long-acting anticholinergic bronchodilators is common but unstudied. Objective: To determine whether combining tiotropium with...

  • Tiotropium reduced exacerbations and health resource use in COPD.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p64 

    This article discusses whether tiotropium is more effective than salmeterol or placebo in reducing exacerbations and health resource use in patients with chronic obstructive pulmonary disease (COPD). Patients who have received tiotropium had fewer COPD exacerbations and exacerbation-days per...

  • Tiotropium more effective than salmeterol in preventing exacerbations of COPD.  // Australian Journal of Pharmacy;Sep2011, Vol. 92 Issue 1096, p102 

    The article presents a study to find whether tiotropium is more effective than salmeterol in preventing exacerbations of chronic obstructive pulmonary disease (COPD).

  • Preventing exacerbations in chronic obstructive pulmonary disease: tiotropium in long-term trials. Dusser, Daniel // Hot Topics in Respiratory Medicine;2011, Vol. 6 Issue 19, p19 

    Exacerbations are acute events that occur with increasing frequency and severity during the course of chronic obstructive pulmonary disease (COPD). Exacerbations induce long-lasting worsening consequences in patients with COPD and may contribute to the progression of the disease. Therefore,...

  • Tiotropium Bromide Inhalation Powder. Keating, Gillian M. // Drugs;2012, Vol. 72 Issue 2, p273 

    The anticholinergic agent tiotropium bromide (Spiriva®) is a long-acting bronchodilator that is indicated for the treatment of chronic obstructive pulmonary disease (COPD). This article reviews the clinical efficacy and tolerability of tiotropium bromide inhalation powder, administered using...

  • Registrar: Improving COPD care. Newson, Louise // GP: General Practitioner;7/1/2005, p53 

    This article presents information on improving the COPD care. COPD is the fourth leading cause of death worldwide and causes over 30,000 deaths a year in Great Britain. Whereas COPD was considered to have few therapeutic options previously, it is now considered treatable because there has been...

  • Would this long-acting bronchodilator be better for your patient? Gwynnei, Mark; Mounsey, Anne // Journal of Family Practice;Feb2012, Vol. 61 Issue 2, p94 

    The article presents a case study of a 60-year-old patient who has a history of exacerbations and chronic obstructive pulmonary disease (COPD). The patient has been using ipratropium and albuterol as medication. The article discusses the addition of tiotropium as a medication regimen for those...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics